Effect of lapatinib on hepatic parenchymal enhancement on gadoxetate disodium (EOB)-enhanced MRI scans.
We present changes seen on hepatobiliary phase (HBP)-gadoxetate disodium (EOB)-enhanced magnetic resonance image of a woman with liver metastases who was treated with lapatinib. After treatment, the HBP images appeared like portal venous phase images. This suggests that lapatinib, an inhibitor of organic anion transporting polypeptide 1B1, one of the substrates of EOB, inhibits EOB uptake by hepatocytes. In patients treated with lapatinib, the ability to diagnose liver tumors on HBP images may be compromised.